Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hillary Prescott"'
Autor:
Hillary Prescott, Julie Kennerly-Shah, Christopher T Elder, Alexandra Shillingburg, Bhavesh Shah, Michael J Reff
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:156-174
The development of BCR-ABL-targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac96c91c822e4bc9f6df5669cf7c029
https://doi.org/10.1177/1078155219864640
https://doi.org/10.1177/1078155219864640
Publikováno v:
American Journal of Health-System Pharmacy. 72:439-447
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of the tyrosine kinase inhibitor (TKI) bosutinib in the management of chronic myeloid leukemia (CML) are reviewed. Summary Although clinical outcomes are favorable in patients wth Phila
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b0afc2a53cda1c717ba42d1a7b7350
https://doi.org/10.2146/ajhp140221
https://doi.org/10.2146/ajhp140221
Publikováno v:
Blood. 132:3234-3234
Introduction: Daratumumab is a first in class immunoglobin G1 kappa human monoclonal antibody that targets the CD38 antigen on the exterior of myeloma cells. Daratumumab provides an important treatment option and has become standard of care for patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38f284bc47630697799fcf99b87c2842
https://doi.org/10.1182/blood-2018-99-111361
https://doi.org/10.1182/blood-2018-99-111361
Autor:
Irene M. Ghobrial, Hillary Prescott, Kaitlen Reyes, Jacob P. Laubach, Houry Leblebjian, Paul G. Richardson, Elaine Xiang
Publikováno v:
Blood. 132:2024-2024
Introduction: Multiple Myeloma (MM) is a hematologic cancer caused by malignant plasma cells. Daratumumab is an immunoglobin G1 kappa human monoclonal antibody that targets CD38 antigen which is a cell surface glycoprotein highly expressed on myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2c3ffc22a77c6f400956ce59cbcd755
https://doi.org/10.1182/blood-2018-99-111191
https://doi.org/10.1182/blood-2018-99-111191
The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. Mutations involving FLT3 are among the most common molecular abnormalities in acute myelogenous leukemia (AML). Available evidence suggests that these molecular lesions con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09e0d26a761a87759e17dd323d00d73
https://europepmc.org/articles/PMC4122233/
https://europepmc.org/articles/PMC4122233/
Publikováno v:
Seminars in hematology. 47(3)
Thrombocytopenia, common in leukemias and myelodysplastic syndromes (MDS), is responsible for increased risk of bleeding and delay of therapy. Platelet transfusions, although effective in increasing platelet counts, are limited by supply, are associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877f791b68094023cc09abbe5fffe6f4
https://pubmed.ncbi.nlm.nih.gov/20620439
https://pubmed.ncbi.nlm.nih.gov/20620439
Autor:
Jean Pierre J. Issa, Jeffrey Bryan, Hagop M. Kantarjian, Hillary Prescott, Elias Jabbour, Guillermo Garcia-Manero
Publikováno v:
Drugs. 70(11)
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments have contributed significantly to advancements in the treatment of MDS: (i) improvements i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0af6c032e88e387fa368e9dc7a5e00
https://pubmed.ncbi.nlm.nih.gov/20614946
https://pubmed.ncbi.nlm.nih.gov/20614946
Autor:
Naval Daver, Daniela Hoehn, Guillermo Garcia-Manero, Hagop M. Kantarjian, Jianhua Hu, Hillary Prescott, Jeffrey Bryan, Jorge E. Cortes, Elias Jabbour, Paolo Strati, Wei Qiao, Susan O'Brien, Navira F Khan, Courtney D. DiNardo, Tapan M. Kadia
Publikováno v:
Blood. 122:2801-2801
Background Epigenetic therapy with HMA is now the standard of care for pts with MDS with complete response (CR) rates of 7% to 35% and median survival of 20 to 24 months (mos). Large studies have demonstrated the relevance of karyotype abnormalities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2122ff069d811e8ec297e2cb34625526
https://doi.org/10.1182/blood.v122.21.2801.2801
https://doi.org/10.1182/blood.v122.21.2801.2801
Autor:
Elias Jabbour, Guillermo Garcia-Manero, Lianchun Xiao, Al Ali Najla, Asmita Mishra, Eric Padron, Jeffrey E Lancet, Jeffery Bryan, Hillary Prescott, David P. Steensma, Mikkael A. Sekeres, Gail J. Roboz, Alan List, Hagop M Kantarjian, Rami S Komrokji
Publikováno v:
Blood. 122:388-388
Background HMA are standard of care in pts with high-risk MDS and commonly used in pts with lower risk. Pts with high-risk disease post HMA failure have a poor prognosis with a median survival of 4-6 months. The prognosis of pts with low and intermed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b08b8a5c8f4261e5fb100b08d31f21f
https://doi.org/10.1182/blood.v122.21.388.388
https://doi.org/10.1182/blood.v122.21.388.388
Publikováno v:
European Oncology & Haematology. :200
Myelodysplastic syndromes (MDS) are a group of heterogeneous haematopoietic stem cell disorders characterised by peripheral blood cytopenias and a risk of transformation to acute myeloid leukaemia. Until recently, treatment of MDS predominately consi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ef37d0618fd52d663aea748ed65fbe5
https://doi.org/10.17925/eoh.2011.07.03.200
https://doi.org/10.17925/eoh.2011.07.03.200